Drug profile · INN
ocriplasmin
JETREA
ocriplasmin (JETREA) is a laminin hydrolytic enzyme. Route of administration: intravitreal. Current US regulatory status: approved.
Drug details — ocriplasmin
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- INTRAVITREAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ocriplasmin (JETREA) is a laminin hydrolytic enzyme. Route of administration: intravitreal. Current US regulatory status: approved.
Key facts
Mechanism of action
Laminin hydrolytic enzyme
Primary target: Collagen
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is ocriplasmin?
ocriplasmin (JETREA) is a laminin hydrolytic enzyme. Route of administration: intravitreal. Current US regulatory status: approved.
What is the brand name for ocriplasmin?
JETREA is a marketed brand name for ocriplasmin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ocriplasmin?
ocriplasmin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.